Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: Correlative study in Japan Clinical Oncology Group Trial JCOG9912

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2560-2565

  Yamada, Y ^a   Boku, N ^b   Nishina, T ^c   Yamaguchi, K ^d   Denda, T ^e   Tsuji, A ^f   Hamamoto, Y ^g   Konishi, K ^h   Tsuji, Y ⁱ   Amagai, K ^j   Ohkawa, S ^k   Fujita, Y ^l   Nishisaki, H ^m   Kawai, H ⁿ   Takashima, A ^a   Mizusawa, J ^o   Nakamura, K ^o   Ohtsu, A ^p  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e CHIBA CANCER CENTER   (Japan)

^f KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^g KEIO UNIVERSITY   (Japan)

^h SHOWA UNIVERSITY   (Japan)

ⁱ Tonan Hospital   (Japan)

^j IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^k KANAGAWA CANCER CENTER   (Japan)

^l YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^m HYOGO CANCER CENTER   (Japan)

ⁿ AICHI CANCER CENTER HOSPITAL   (Japan)

^o NATIONAL CANCER CENTER   (Japan)

^p NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

more..

Author keywords

Dihydropyrimidine dehydrogenase; Excision repair cross complementing gene 1; Gastric cancer; Prognostic factor; Thymidylate synthase; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; ENDOTHELIAL CELL GROWTH FACTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MESSENGER RNA; THYMIDYLATE SYNTHASE; VASCULOTROPIN A;

ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; EGFR GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MOLECULAR DYNAMICS; MTHFR GENE; ONCOGENE; OPRT GENE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STOMACH BIOPSY; STOMACH CANCER; SURVIVAL RATE; TOPO 1 GENE; VEGF A GENE;

DIHYDROPYRIMIDINE DEHYDROGENASE; EXCISION REPAIR CROSS-COMPLEMENTING GENE 1; GASTRIC CANCER; PROGNOSTIC FACTOR; THYMIDYLATE SYNTHASE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DIHYDROURACIL DEHYDROGENASE (NADP); DNA-BINDING PROTEINS; DRUG COMBINATIONS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; MALE; OXONIC ACID; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL; TEGAFUR; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884705232     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt238     Document Type: Article

References (23)

1. Chau I, Norman AR, Cunningham D et al Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22: 2395-2403.
2. Metzger R, Leichman CG, Danenberg KD et al ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316.
3. Wei J, Zou Z, Qian X et al ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98: 1398-1402.
4. Ichikawa W, Takahashi T, Suto K et al Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 2006; 119: 1927-1933.
5. Lenz HJ, Leichman CG, Danenberg KD et al Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-182.
6. Johnston PG, Lenz HJ, Leichman CG et al Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-1412.
7. Matsubara J, Yamada Y, Hirashima Y et al Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 2008; 14: 3022-3029.
8. Kwon HC, Roh MS, Oh SY et al Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18: 504-509.
9. Boku N, Yamamoto S, Fukuda H et al Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
10. McShane LM, Altman DG, Sauerbrei W et al Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
11. Parker RJ, Eastman A, Bostick-Bruton F et al Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772-777.
12. Satoh A, Toyota M, Itoh F et al Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003; 63: 8606-8613.
13. Smith S, Su D, Rigault de la Longrais IA et al ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007; 25: 5172-5179.
14. Mancuso A, Sacchetta S, Saletti PC et al Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer Res 2010; 30: 4289-4295.
15. Lord RV, Brabender J, Gandara D et al Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291.
16. Wilson MD, Ruttan CC, Koop BF et al ERCC1: a comparative genomic perspective. Environ Mol Mutagen 2001; 38: 209-215.
17. Chen HY, Shao CJ, Chen FR et al Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer 2010; 126: 1944-1954.
18. Carethers JM, Chauhan DP, Fink D et al Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-131.
19. An C, Choi IS, Yao JC et al Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11: 656-663.
20. Locker GY, Hamilton S, Harris J et al ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
21. Smorenburg CH, Peters GJ, van Groeningen CJ et al Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17: 35-42.
22. Scartozzi M, Loretelli C, Berardi R et al Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Dig Liver Dis 2012; 44: 74-79.
23. Grem JL, Danenberg KD, Behan K et al Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res 2001; 7: 999-1009.